Stock Play ~ITNS Good Morning Traders, most our

New Post Public Reply Private Reply Replies (0) Message Board
bestdamnpennies

Stock Play ~ITNS

Good Morning Traders, most our attention the first part of this week will be on ITNS .012?s.  Chart confirmed bottom play with solid news out this morning! We are sitting right above 52 week low with support.  We expect major attention on ITNS throughout the week starting with this morning’s News. This could really make a big move once we break .02+

Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, Creates Itonis Pharmaceuticals, Prepares to Announce Clinical Trial http://finance.yahoo.com/news/charles-hensley...ml

IRVINE, CA–(Marketwire – Oct 1, 2012) –  Itonis, Inc. ( PINKSHEETS : ITNS ) and Charles Hensley, Ph.D., the inventor of the Zicam® Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to announce that the organization of the first clinical trial of the recently announced over-the-counter and prescription homeopathic nasal spray for the treatment of nausea has commenced. The company plans to announce over the coming weeks full details of the double blinded, placebo-controlled clinical trial.

Dr. Hensley commented, “I’ve been working on the formulation for an over-the-counter, systemically active preparation delivered via a nasal spray for the alleviation of mild to moderate nausea. While there is considerable anecdotal indication that this preparation will be both safe and effective, we feel it is time for the rubber to meet the road in an Institutional Review Board controlled clinical study setting. We are actively organizing the study and look forward to announcing full details very soon.”

While the size of the market for anti-nausea related drugs and preparations is not exactly known, Itonis estimates it to be well in excess of $1 billion annually. There have been relatively few innovations within this product category over the past few years and the company believes the market is ripe for a new type of anti-nausea preparation to be available over-the-counter.

About Itonis, Inc. and Itonis Pharmaceuticals
Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division’s mission is to create and market over-the-counter and prescription homeopathic products that better people’s lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. He and his team plan to use the same methodologies to revolutionize the treatments of several other common ailments and other chronic diseases.

VIDEO CHART:



About Itonis Pharmaceuticals

Itonis Pharmaceuticals, a new division of Itonis, Inc., is led by Charles Hensley, Ph.D. This division’s mission is to create and market over-the-counter and prescription homeopathic products that better people’s lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States.

Please visit www.itonisholdings.com .

Itonis, Inc. is an Orange County, California based holding company.  We were established in 2005 and are currently undergoing a company-wide transformation to embark upon an aggressive acquisition plan to purchase high growth entrepreneurial companies that have established themselves, or are expected to establish themselves as leaders in various market niches.

The company has relocated its headquarter offices to Orange County, CA in order to invigorate its operations and to implement company growth plans. A newly formed executive management team has been put in place, along with the appointment of a new board of directors. The transition is well underway.

The incoming management team brings decades of experience as successful business leaders and entrepreneurs who are dedicated to the planned vision of acquiring small companies with high growth potential. The executive team and its board of directors are well positioned to steer the company into a profitable future and are looking forward to the first of many exciting and successful years to come.

ITNS Bottom Chart:

Recent Headlines:

Monday, October 1, 2012

Thursday, August 23, 2012

Monday, August 20, 2012

Thursday, August 16, 2012

Friday, July 6, 2012

Friday, June 29, 2012

Wednesday, May 23, 2012

Tuesday, May 22, 2012

Monday, May 7, 2012

Friday, April 20, 2012

http://bestdamnpennies.com/disclaimer.html

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

WeightWatchers Shifts 2025 Earnings Call for Key Accounting Updates

Updated Category News Views 154

WeightWatchers Adjusts Schedule for 2025 Earnings Report WW International, Inc. (NASDAQ: WW), widely recognized for its innovative weight management solutions, has made an important change regarding its upcoming earnings report. The company has rescheduled its earnings release and associated conference call originally intended for August 5, 2025. This Rescheduling is...

Continue Reading
Investors Alert: Key Investigations into Regeneron Pharmaceuticals

Updated Category News Views 120

Investors Take Note: Faruqi & Faruqi Seeks to Help Faruqi & Faruqi, LLP, a prominent national securities litigation firm, is leading an investigation focusing on investors who may have sustained significant losses with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The firm encourages those who believe they have suffered losses of over $100,000 due to the company’s...

Continue Reading
Waller's Bold Critique of Powell: A Call for Rate Cuts

Updated Category News Views 233

Waller’s Challenge to Economic Caution Federal Reserve Governor Christopher Waller has made headlines by challenging the stance of Chairman Jerome Powell, particularly regarding his assertion that economic data is too sparse to draw clear conclusions. Waller believes the Fed should proceed with easing monetary policy, even amidst perceived gaps in information. Ending...

Continue Reading
Michael John Politis Recognized as Elite Attorney in America

Updated Category News Views 276

Michael John Politis Achieves National Recognition Michael John Politis, a distinguished attorney at Politis & Matovina, P.A., has garnered significant acclaim by being recognized as a member of the Nation's Top One Percent. This prestigious acknowledgment is bestowed by the National Association of Distinguished Counsel (NADC). The NADC is committed to upholding the...

Continue Reading
Home Buying Opportunities: Navigating the Market's Shift

Updated Category News Views 74

Introduction For many home buyers, fall typically signals a slow down in the housing market. But this year, things might unfold differently. With mortgage rates dropping and inventory on the rise, buyers could have a chance to find their dream homes during what is usually seen as the offseason. Affordability Improves The recent decline in monthly mortgage payments has...

Continue Reading